Abdul Mannan on CVT risk with CHC: It is Not One-Size-Fits-All!
Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, shared on LinkedIn:
”CVT risk with CHC is not one-size-fits-all.
The type of progestin matters enormously (fourth-generation worst), and the multiplication of risk factors (family history, thrombophilia, obesity) creates scenarios with 200+ fold increased risk.
Most important clinical change:
- Take family history more seriously – it predicts risk independently of thrombophilia testing.
- And if you’re prescribing CHC, think twice about fourth-generation progestins.
The absolute risk remains low for most women, but for that high-risk subset (family history + thrombophilia), the numbers are sobering enough to have serious conversations about alternative contraception.”
Read the full article in JTH.
Article: The risk of cerebral vein thrombosis associated with different types of combined hormonal contraceptives: a case-control study
Authors: Maria Abbattista, Addolorata Truma, Ida Martinelli, Francesca Gianniello, Serena M. Passamonti, Marco Capecchi, Andrea Artoni, Flora Peyvandi, Paolo Bucciarelli
Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
Oct 3, 2025, 07:53Pancytopenia in Pregnancy: A Time-Critical Hematological Emergency
-
Oct 2, 2025, 14:12Helen McPherson at ISFP-IFRS 2025: Fibrin Clot Structure and Function Modulation by Targeting Fibrinogen aC Region
-
Oct 2, 2025, 10:48Kanishk Kumar: TFPI Market Size - Advancing Hemostasis and Antithrombotic Therapy
-
Oct 2, 2025, 07:31Non-Invasive Management of Radial Artery Pseudoaneurysm
-
Oct 2, 2025, 07:28Mohamed Gamal: Rethinking The Standard of Care for Deep Vein Thrombosis Management
-
Oct 3, 2025, 14:00Quentin Van Thillo Shares His Latest Article on VWD: Grateful to Have Worked with Cedric Hermans
-
Oct 3, 2025, 13:40Cihan Ay and Colleagues on Thromboembolism and Bleeding in Multiple Myeloma
-
Oct 3, 2025, 13:27Laura Haynes: This Was Such a Fun and Collaborative Project to Be a Part of!
-
Oct 3, 2025, 12:40Christian Pfrepper and Team's Letter on Emicizumab Plasma Concentration Measurment in EDTA plasma
-
Oct 3, 2025, 12:00Giuseppe Lippi and Colleagues on the Impact of Hemolysis on Coagulation Testing
-
Oct 3, 2025, 15:31Anirban Sen Gupta and Andrew Shoffstall Collaboration on Bioinspired Synthetic Platelet Systems for Brain Injury Treatment
-
Oct 3, 2025, 15:07Shai Shen-Orr: Excited to Share that The Human Immunome Project (HIP) Has Launched Its Scientific Partner Network
-
Oct 2, 2025, 04:59Caterina Casari - Prizes for Innovators 2025 Winner!
-
Oct 2, 2025, 04:572025 Innovators Award: Ile de France Région Recognizes 3 Researchers Who Have Committed Themselves to The Innovation
-
Oct 1, 2025, 15:59Anirban Sen Gupta: Thrilled to share a great collaboration story in Nature Portfolio
-
Oct 3, 2025, 14:48Maha Othman - Elected as the Co-Lead for the Basic and Translational Research Platform at CanVECTOR Research Network
-
Oct 3, 2025, 14:41Maria Elisa Mancuso: A Real Pleasure to Participate in The Policy Roundtable on Future of Haemophilia Care in Egypt
-
Oct 2, 2025, 04:37Louise Bannon: Did You Know that 1 in 4 People Lose Their Lives to Blood Clot-Related Conditions?
-
Oct 1, 2025, 16:35World Thrombosis Day 2025․ 8 Ways to Take Control and Save Lives
-
Oct 1, 2025, 12:30World Stroke Academy "Antithrombotic Therapy for Atherosclerotic Stroke Prevention" Webinar is Now Available to Record